<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740869</url>
  </required_header>
  <id_info>
    <org_study_id>HE12-021</org_study_id>
    <secondary_id>Autism uanl</secondary_id>
    <nct_id>NCT01740869</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders</brief_title>
  <acronym>Autism</acronym>
  <official_title>Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the plasticity of autologous intrathecal
      hematopoietic cells would improve the neurologic and the social skills of pediatric patients
      with autism spectrum disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is accumulating evidence that shows that the administration of hematopoietic cells into
      the brain in the patients with spectrum autism could help in the physiopathology of the
      illness.

      It has been found that after introducing hematopoietic cells in the subarachnoid space of the
      spinal cord, these cells may be transported through the cerebrospinal fluid and can be
      delivered more efficiently to the injured area, when compared to the intravenous route.

      Patients will be stimulated for 3 consecutive days with granulocyte colony stimulating factor
      (G-CSF) and then their bone marrow will be harvested according to their weight. Bone marrow
      will be processed in order to obtain CD34+ cells and minimize the amount of red blood cells.
      An inoculum of 5 to 10mL of stem cells will be infused intrathecally. Patients will be
      evaluated with two scales &quot;CARS&quot; and the &quot;IDEA&quot; also we will check the clinical history. On
      days 0, 30 and 180.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IDEA Improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement in IDEA evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CARS improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement in CARS evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Autism</condition>
  <condition>Autism Spectrum</condition>
  <arm_group>
    <arm_group_label>Experimental: Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children who will receive intrathecal autologous stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Crossover</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stem cells</intervention_name>
    <arm_group_label>Experimental: Patients</arm_group_label>
    <arm_group_label>Control/Crossover</arm_group_label>
    <other_name>Bone marrow harvest and aspirate stem cells.</other_name>
    <other_name>Intrathecal stem cell aplication autologous stem cells into the spinal canal.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children with autism spectrum DSM4-TR

        Exclusion Criteria:

          -  Patients with neurodegenerative or autoimmune diseases.

          -  Patients with active infection in any organ or tissue at the time of entering the
             study, the onset of stimulation with G-CSF or at the procedure.

          -  Patients who do not sign the informed consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Villarreal-Martinez, MD</last_name>
    <phone>+52 81 83 48 61 36</phone>
    <phone_ext>413</phone_ext>
    <email>dr_lauravillarreal@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Consuelo Mancias-Guerra, MD</last_name>
    <phone>+52 81 83 48 61 36</phone>
    <phone_ext>413</phone_ext>
    <email>consuelomanciasg@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology Service, Hospital Universitario Dr. Jose E. Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Villarreal-Martinez, MD</last_name>
      <phone>+52 81 83 48 61 36</phone>
      <phone_ext>413</phone_ext>
      <email>dr_lauravillarreal@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Siniscalco D, Sapone A, Cirillo A, Giordano C, Maione S, Antonucci N. Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future? J Biomed Biotechnol. 2012;2012:480289. doi: 10.1155/2012/480289. Epub 2012 Feb 13. Review.</citation>
    <PMID>22496609</PMID>
  </reference>
  <reference>
    <citation>Ichim TE, Solano F, Glenn E, Morales F, Smith L, Zabrecky G, Riordan NH. Stem cell therapy for autism. J Transl Med. 2007 Jun 27;5:30. Review.</citation>
    <PMID>17597540</PMID>
  </reference>
  <reference>
    <citation>Mehta T, Feroz A, Thakkar U, Vanikar A, Shah V, Trivedi H. Subarachnoid placement of stem cells in neurological disorders. Transplant Proc. 2008 May;40(4):1145-7. doi: 10.1016/j.transproceed.2008.03.026.</citation>
    <PMID>18555135</PMID>
  </reference>
  <reference>
    <citation>Hayashi T, Iwai M, Ikeda T, Jin G, Deguchi K, Nagotani S, Zhang H, Sehara Y, Nagano I, Shoji M, Ikenoue T, Abe K. Neural precursor cells division and migration in neonatal rat brain after ischemic/hypoxic injury. Brain Res. 2005 Mar 15;1038(1):41-9.</citation>
    <PMID>15748871</PMID>
  </reference>
  <reference>
    <citation>Nakatomi H, Kuriu T, Okabe S, Yamamoto S, Hatano O, Kawahara N, Tamura A, Kirino T, Nakafuku M. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell. 2002 Aug 23;110(4):429-41.</citation>
    <PMID>12202033</PMID>
  </reference>
  <reference>
    <citation>Goldman SA, Schanz S, Windrem MS. Stem cell-based strategies for treating pediatric disorders of myelin. Hum Mol Genet. 2008 Apr 15;17(R1):R76-83. doi: 10.1093/hmg/ddn052. Review.</citation>
    <PMID>18632701</PMID>
  </reference>
  <reference>
    <citation>Rempe DA, Kent TA. Using bone marrow stromal cells for treatment of stroke. Neurology. 2002 Aug 27;59(4):486-7.</citation>
    <PMID>12196638</PMID>
  </reference>
  <reference>
    <citation>Felling RJ, Snyder MJ, Romanko MJ, Rothstein RP, Ziegler AN, Yang Z, Givogri MI, Bongarzone ER, Levison SW. Neural stem/progenitor cells participate in the regenerative response to perinatal hypoxia/ischemia. J Neurosci. 2006 Apr 19;26(16):4359-69.</citation>
    <PMID>16624956</PMID>
  </reference>
  <reference>
    <citation>Gordon PH, Yu Q, Qualls C, Winfield H, Dillon S, Greene PE, Fahn S, Breeze RE, Freed CR, Pullman SL. Reaction time and movement time after embryonic cell implantation in Parkinson disease. Arch Neurol. 2004 Jun;61(6):858-61.</citation>
    <PMID>15210522</PMID>
  </reference>
  <reference>
    <citation>Kulbatski I, Mothe AJ, Nomura H, Tator CH. Endogenous and exogenous CNS derived stem/progenitor cell approaches for neurotrauma. Curr Drug Targets. 2005 Feb;6(1):111-26. Review.</citation>
    <PMID>15720218</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2012</study_first_submitted>
  <study_first_submitted_qc>November 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>M.D Laura Villarreal Martinez</investigator_full_name>
    <investigator_title>Hematology Service</investigator_title>
  </responsible_party>
  <keyword>autism</keyword>
  <keyword>autism spectrum</keyword>
  <keyword>stem cells</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

